{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:11:59Z","timestamp":1781561519206,"version":"3.54.5"},"reference-count":206,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Targeted therapies continue to change the landscape of lymphoma treatment, resulting in improved therapy options and patient outcomes. Numerous agents are now approved for use in the indolent lymphomas and many others under development demonstrate significant promise. In this article, we review the landscape of targeted agents that apply to the indolent lymphomas, predominantly follicular lymphoma, lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinaemia and marginal zone lymphoma. The review covers small molecule inhibitors, immunomodulators and targeted immunotherapies, as well as presenting emerging and promising combination therapies.<\/jats:p>","DOI":"10.3390\/cancers14051276","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:17:03Z","timestamp":1646122623000},"page":"1276","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-2024","authenticated-orcid":false,"given":"Adrian","family":"Minson","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted Therapy in Chronic Lymphocytic Leukemia","volume":"25","author":"Kipps","year":"2019","journal-title":"Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: Mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/1060028020909117","article-title":"Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents","volume":"54","author":"Buege","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: New targets and novel therapies","volume":"11","author":"Cheson","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_7","first-page":"S2152","article-title":"The Novel Therapeutic Landscape for Relapsed\/Refractory Diffuse Large B Cell Lymphoma","volume":"21","author":"Nuvvula","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood.2020006783","article-title":"Resistance to Bruton\u2019s Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies","volume":"138","author":"Stephens","year":"2021","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: Preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.2020006784","article-title":"Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2217\/fon.14.51","article-title":"Ibrutinib: A first in class covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"10","author":"Davids","year":"2014","journal-title":"Future Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"Furman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as Treatment for Patients with Relapsed\/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study","volume":"23","author":"Gopal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: Long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134611","article-title":"Efficacy and Safety of Zanubrutinib in Patients with Relapsed\/Refractory Marginal Zone Lymphoma: Initial Results of the Magnolia (BGB-3111-214) Trial","volume":"136","author":"Opat","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: A single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood-2021-146744","article-title":"Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton\u2019s Tyrosine Kinase Inhibitor, in Patients with Treatment-Na\u00efve or Relapsed\/Refractory Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"138","author":"Suzuki","year":"2021","journal-title":"Blood."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2021-149350","article-title":"Efficacy and Safety of Orelabrutinib in Relapsed\/Refractory Waldenstrom\u2019s Macroglobulinemia Patients","volume":"138","author":"Zhou","year":"2021","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","unstructured":"Hillmen, P., Eichhorst, B., Brown, J.R., Lamanna, N., O\u2019Brien, S., Tam, C.S., Qiu, L., Kazmierczak, M., Zhou, K., and \u0160imkovi\u010d, M. (2021, January 11). First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Proceedings of the 2021 European Hematology Association Virtual Congress."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"668162","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of Patients with Relapsed or Refractory Mantle\u2013Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lewis, K.L., and Cheah, C.Y. (2021). Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080764"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Allan, J.N., Pinilla-Ibarz, J., Gladstone, D.E., Patel, K., Sharman, J.P., Wierda, W.G., Choi, M.Y., O\u2019Brien, S.M., Shadman, M., and Davids, M.S. (2021). Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica.","DOI":"10.3324\/haematol.2021.280061"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-138946","article-title":"A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)","volume":"136","author":"Minson","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/blood-2019-126186","article-title":"A CD19\/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib","volume":"134","author":"Mhibik","year":"2019","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a Dual PI3K\u03b4\/CK1\u03b5 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2147\/CMAR.S201024","article-title":"Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic","volume":"13","author":"Chauhan","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40264-018-0778-4","article-title":"Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology","volume":"42","author":"Curigliano","year":"2019","journal-title":"Drug Saf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wright, S.C.E., Vasilevski, N., Serra, V., Rodon, J., and Eichhorn, P.J.A. (2021). Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers, 13.","DOI":"10.3390\/cancers13071538"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"670275","DOI":"10.3389\/fonc.2021.670275","article-title":"Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas","volume":"11","author":"Yu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2016000976","article-title":"Combinations of idelalisib with rituximab and\/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma","volume":"1","author":"Coutre","year":"2016","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","article-title":"Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Tomowiak","year":"2021","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/bloodadvances.2020001584","article-title":"PI3K\u03b4 inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax","volume":"4","author":"Serrat","year":"2020","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 inhibitors and MCL1 inhibitors for hematological malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_68","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2019-121424","article-title":"Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2019-126396","article-title":"Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2021-148451","article-title":"Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed\/Refractory (R\/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib","volume":"138","author":"Tam","year":"2021","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/blood-2021-145936","article-title":"BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Trial in Progress)","volume":"138","author":"Mato","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134392","article-title":"Ibrutinib Plus Venetoclax in Patients With Relapsed\/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1200\/JCO.2021.39.15_suppl.7534","article-title":"Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL): Primary analysis of a phase 1b\/2 trial","volume":"39","author":"Bannerji","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1182\/blood-2019-126242","article-title":"Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma","volume":"134","author":"Christian","year":"2019","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood-2012-12-451799","article-title":"Mechanisms of epigenetic deregulation in lymphoid neoplasms","volume":"121","author":"Jiang","year":"2013","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2217\/fon-2020-1244","article-title":"EZH2 inhibition by tazemetostat: Mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma","volume":"17","author":"Julia","year":"2021","journal-title":"Future Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Grossmann","year":"2013","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/bloodadvances.2020002773","article-title":"Treating lymphoma is now a bit EZ-er","volume":"5","author":"Morin","year":"2021","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2021-151452","article-title":"Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat","volume":"138","author":"Dave","year":"2021","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, Signaling, and Treatment of Waldenstr\u00f6m Macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_89","first-page":"4","article-title":"Trial in Progress: A Phase 2, Single-Arm, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/blood-2021-148199","article-title":"Interim Analysis of the Randomized Phase 1b\/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed\/Refractory Follicular Lymphoma","volume":"138","author":"Batlevi","year":"2021","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428194.2020.1775210","article-title":"Selinexor for advanced hematologic malignancies","volume":"61","author":"Walker","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-20-4929","article-title":"Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study","volume":"27","author":"Seymour","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: Rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.clml.2019.09.081","article-title":"A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma","volume":"19","author":"Spencer","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/leu.2016.213","article-title":"Survival control of malignant lymphocytes by anti-apoptotic MCL-1","volume":"30","author":"Spinner","year":"2016","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.humpath.2004.04.018","article-title":"MCL-1 expression in B-cell non-Hodgkin\u2019s lymphomas","volume":"35","author":"Rassidakis","year":"2004","journal-title":"Hum. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: An important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Medeiros","year":"2012","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10637-021-01141-2","article-title":"Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors","volume":"39","author":"Italiano","year":"2021","journal-title":"Invest. New Drugs"},{"key":"ref_105","first-page":"1","article-title":"A phase Ib\/II study of idasanutlin in combination with obinutuzumab or rituximab in patients with follicular lymphoma or diffuse large B-cell lymphoma","volume":"4","author":"Trepel","year":"2020","journal-title":"HemaSphere"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-136221","article-title":"Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R\/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I\/II Study","volume":"136","author":"Kamdar","year":"2020","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2559.2002.01506.x","article-title":"Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin\u2019s lymphoma","volume":"41","author":"Nielsen","year":"2002","journal-title":"Histopathology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/10428194.2020.1842399","article-title":"Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: Current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"Onco. Targets. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/leu.2016.52","article-title":"BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells","volume":"30","author":"Xu","year":"2016","journal-title":"Leukemia"},{"key":"ref_112","first-page":"4048","article-title":"Preliminary Results from an Ongoing Phase 1\/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies","volume":"130","author":"Rosen","year":"2017","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","article-title":"BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study","volume":"126","author":"Abramson","year":"2015","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/bloodadvances.2021004619","article-title":"Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma","volume":"5","author":"Dickinson","year":"2021","journal-title":"Blood Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","article-title":"An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"184","author":"Andorsky","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"21004","DOI":"10.1073\/pnas.1111708108","article-title":"Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region","volume":"108","author":"Yu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/med.21799","article-title":"MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies","volume":"41","author":"Liang","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"19946","DOI":"10.1073\/pnas.0907511106","article-title":"Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma","volume":"106","author":"Hailfinger","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Seshadri, M.R., and Melnick, A.M. (2021). Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leuk. Lymphoma, 1\u201310.","DOI":"10.1080\/10428194.2021.1999444"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2021-153159","article-title":"Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies","volume":"138","author":"Yin","year":"2021","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2021-153855","article-title":"MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma","volume":"138","author":"Seshadri","year":"2021","journal-title":"Blood"},{"key":"ref_126","first-page":"5690","article-title":"Discovery of JNJ-67856633: A Novel, First-in-Class MALT1 Protease Inhibitor for the Treatment of B Cell Lymphomas","volume":"136","author":"Philippar","year":"2020","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jha2.2","article-title":"Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma","volume":"1","author":"Torka","year":"2020","journal-title":"eJHaem"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","article-title":"Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed\/Refractory Multiple Myeloma or Lymphoma","volume":"22","author":"Shah","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood-2021-146345","article-title":"A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed\/Refractory (R\/R) Non-Hodgkin Lymphoma (NHL)","volume":"138","author":"Torka","year":"2021","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Li, B., Wan, Q., Li, Z., and Chng, W.-J. (2021). Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. Cancers, 13.","DOI":"10.3390\/cancers13205147"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.1002\/ajh.25387","article-title":"Efficacy and safety of the dual SYK\/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study","volume":"94","author":"Hamlin","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2021-148313","article-title":"Phase 2a Study of the Dual SYK\/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed\/Refractory Follicular Lymphoma","volume":"138","author":"Hamlin","year":"2021","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: Cell fate control and signal integration in development","volume":"284","author":"Rand","year":"1999","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e2019037","DOI":"10.4084\/mjhid.2019.037","article-title":"Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies","volume":"11","author":"Sorrentino","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"29804","DOI":"10.18632\/oncotarget.7772","article-title":"Notch signaling: Its roles and therapeutic potential in hematological malignancies","volume":"7","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_143","first-page":"40","article-title":"Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2021.39.15_suppl.7508","article-title":"Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed\/refractory follicular lymphoma (r\/r FL): Primary analysis of the phase 2 Elara trial","volume":"39","author":"Schuster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"2","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/hematology.2019000031","article-title":"Targeting CD20: Teaching an old dog new tricks","volume":"2019","author":"Sharman","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3816\/CLM.2009.n.015","article-title":"Rituximab-based treatments in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Dimopoulos","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: Results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_151","first-page":"148","article-title":"Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/13543784.2018.1492549","article-title":"CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas","volume":"27","author":"Watkins","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-019-02635-9","article-title":"A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma","volume":"109","author":"Ohmachi","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood.V122.21.1810.1810","article-title":"Safety Profile and Clinical Response to MEDI-551, a Humanized Monoclonal Anti-CD19, in a Phase 1\/2 Study in Adults with Relapsed or Refractory Advanced B-Cell Malignancies","volume":"122","author":"Hamadani","year":"2013","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: Clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet. Haematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: A cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_161","unstructured":"Budde, L.E. (2021, January 12). Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results from a Phase Ib\/II Study Abstract #533. Proceedings of the 2021 ASH Annual Meeting, Atlanta, GA, USA."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2021-148359","article-title":"Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib\/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"138","author":"Hutchings","year":"2021","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2021-146800","article-title":"Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma","volume":"138","author":"Sachini","year":"2021","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-15-2488","article-title":"Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed\/Refractory CD22+ B-cell Non-Hodgkin Lymphoma","volume":"22","author":"Ogura","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst. Biol. Appl."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cts.12662","article-title":"A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities","volume":"12","author":"Chen","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) Who Have Received \u22652 Prior Lines of Therapy: Pivotal Results from a Phase I\/II Study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","article-title":"Glofitamab CD20-TCB bispecific antibody","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Cremasco, F., Menietti, E., Speziale, D., Sam, J., Sammicheli, S., Richard, M., Varol, A., Klein, C., Umana, P., and Bacac, M. (2021). Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS ONE, 16.","DOI":"10.1101\/2020.10.09.332874"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R\/R) Follicular Lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2021-146845","article-title":"Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed\/Refractory (R\/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)","volume":"138","author":"Dickinson","year":"2021","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.pathol.2021.02.002","article-title":"CAR-T cell therapy: Practical guide to routine laboratory monitoring","volume":"53","author":"Selim","year":"2021","journal-title":"Pathology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1470-2045(21)00648-3","article-title":"CAR T-cell therapy for indolent lymphoma: A new treatment paradigm?","volume":"23","author":"Holtzman","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2021-146602","article-title":"A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies","volume":"138","author":"Dickinson","year":"2021","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Bachiller, M., Battram, A.M., Perez-Amill, L., and Mart\u00edn-Antonio, B. (2020). Natural Killer Cells in Immunotherapy: Are We Nearly There?. Cancers, 12.","DOI":"10.3390\/cancers12113139"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"611163","DOI":"10.3389\/fimmu.2020.611163","article-title":"Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology","volume":"11","author":"Schmidt","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model","volume":"11","author":"Reddy","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_198","first-page":"1531","article-title":"Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy","volume":"130","author":"Chiu","year":"2017","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment?","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.2147\/DDDT.S281614","article-title":"An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date","volume":"15","author":"Yilmaz","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom\u2019s macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.24175","article-title":"Lenalidomide is safe and active in Waldenstr\u00f6m macroglobulinemia","volume":"90","author":"Fouquet","year":"2015","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1276\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:30:14Z","timestamp":1760135414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":206,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14051276"],"URL":"https:\/\/doi.org\/10.3390\/cancers14051276","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}